Direct answers, with the sources attached.

BPC-157 has not completed a human safety trial. FDA's May 2026 safety review identified only five small human studies, with no reported serious adverse events but also no adequate safety monitoring or chronic-use data. FDA staff concluded in May 2026 that the evidence weighs against placing it on the compounding list. HHS has since said it does not intend to take enforcement action against licensed compounders who meet its conditions. That is not a safety finding. The honest answer is unknown, not safe or dangerous.

No. Compounded semaglutide is not the same as Ozempic. Ozempic is one approved product made by Novo Nordisk [1, 8]. The main difference in compounded semaglutide vs Ozempic is review: the FDA does not check compounded drugs for safety, effectiveness or quality before they are sold [5]. As of October 2026, the shortage exception that allowed wide compounding has been closed since 2025 [2].

As of September 2026, no. Pentadeca arginate is a name sellers and compounders use for a chemically modified BPC-157, with an added arginine salt claimed to improve stability. No peer-reviewed study of pentadeca arginate itself exists, in people or in animals. BPC-157 has no completed randomized human trial either.

As of September 2026, not exactly. TB-500 is a seller's name for thymosin beta-4 or a piece of it, with no agreed chemical identity. Thymosin beta-4 is the natural protein, and a developer's lab-made version went through human trials. No human trial has tested anything sold as TB-500.

No. A peptide is a chain of amino acids. A steroid is a fat-like molecule with a set chemical structure, and US law defines an anabolic steroid by its relation to testosterone. As of October 2026, sport bans many peptides anyway: WADA lists them in a class of their own, and BPC-157 is banned at all times.

'Research use only' means a product is labelled for lab research and not for people. It is a labelling category, and no regulator has assessed the material for human use. US and EU law judge a product by its intended use, so the label does not change what a product legally is, and it guarantees nothing about purity.

BPC-157 has no FDA drug approval. It is not a DEA-scheduled controlled substance. As of October 2026 it is not on the FDA's 503A compounding bulks list. Since 28 October 2026, HHS says it does not intend to take enforcement action against licensed pharmacies and physicians who compound BPC-157 acetate under ten conditions. In the EU, no marketing authorisation or registered clinical trial exists. Selling it labelled research use only for human use does not change any of this.

As of September 2026, Scenesse. It is the brand name of afamelanotide, an approved medicine in the US and the EU for adults with EPP, a rare disorder of painful skin reactions to light. Melanotan II has never been approved by the FDA or the EMA.

No. Zepbound is one approved product, made by Eli Lilly, and its approval covers that product. As of October 2026, compounded tirzepatide is not FDA approved, and the FDA does not review it for safety, effectiveness or quality before it is sold. The tirzepatide shortage that allowed wide compounding was declared over in December 2024.

Legitimacy signals include a bulk substance made at an FDA-registered establishment, a valid certificate of analysis, and, in the EU, a manufacturer listed in EudraGMDP. None of this is verified by the seller's own label. Research use only labelling has no bearing on legitimacy and does not exempt a seller from enforcement.

A certificate of analysis typically reports HPLC purity, mass-spectrometry identity, and sometimes endotoxin testing, three separate measurements. None of these results mean anything without a validated method behind them, covering accuracy, precision and specificity. A certificate that omits method, reference standard, or contamination data is reporting less than a full quality picture.